

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: May 28, 2008

ATTY DOCKET NO.  
2006\_1150ASERIAL NO.  
10/586,499APPLICANT  
Kyogo ITOH et al.FILING DATE  
April 27, 2007GROUP  
1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/RL/	BA	00/18895	4/2000	WO	_____	_____	
/RL/	BB	2004/067029	8/2004	WO	_____	_____	Abstract
	BC						
	BD						
	BE						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/RL/	CA	Y. Lu et al., "Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor", The Journal of Immunology, Vol. 170, No. 6, pp. 3162-3170, March 15, 2003.
↓	CB	H. Takedatsu et al., "Expression of Epithelial Cancer-Related Antigens in Hematologic Malignancies Applicable for Peptide-Based Immunotherapy", Journal of Immunotherapy, Vol. 27, pp. 289-297, 1997.
↓	CC	T. Mine et al., "Immunological Evaluation of CTL Precursor-Oriented Vaccines for Advanced Lung Cancer Patients", Cancer Science, Vol. 94, No. 6, pp. 548-556, June 6, 2003.
↓	CD	G. Gonzalez et al., "Epidermal Growth Factor-Based Cancer Vaccine for Non-Small-Cell Lung Cancer Therapy", Annals of Oncology, Vol. 14, No. 3, pp. 461-466, March 2003.
↓	CE	R. S. Herbst et al., "Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer", Clinical Cancer Research, Vol. 9, pp. 5813-5824, December 1, 2003.
↓	CF	H. Shomura et al., "Identification of Epidermal Growth Factor Receptor-Derived Peptides Immunogenic for HLA-A2* Cancer Patients", British Journal of Cancer, Vol. 90, No. 8, pp. 1563-1571, April 19, 2004.
	CG	

EXAMINER /Robert Landsman/

DATE CONSIDERED

11/15/2008